Pentostatin
- Generic Name
- Pentostatin
- Brand Names
- Nipent
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 53910-25-1
- Unique Ingredient Identifier
- 395575MZO7
- Background
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
- Indication
For the treatment of hairy cell leukaemia refractory to alpha interferon.
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00506922
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT00496873
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Pentostatin and Targeted Busulfan
- Conditions
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2014-06-05
- Target Recruit Count
- 42
- Registration Number
- NCT00496340
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Alemtuzumab and Pentostatin In T-cell Neoplasms
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT00453193
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 14
- Registration Number
- NCT00402714
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Tufts-New England Medical Center, Boston, Massachusetts, United States
🇺🇸Methodist Hospital - Texas Transplant Institute, San Antonio, Texas, United States
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 184
- Registration Number
- NCT00254163
- Locations
- 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸St Joseph Oncology, Inc, St Joseph, Missouri, United States
🇺🇸Alliance Hematology Oncology PA, Westminster, Maryland, United States
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 180
- Registration Number
- NCT00224874
- Locations
- 🇺🇸
DFCI/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-02-08
- Target Recruit Count
- 28
- Registration Number
- NCT00201721
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-04-27
- Target Recruit Count
- 8
- Registration Number
- NCT00201786
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-03
- Target Recruit Count
- 60
- Registration Number
- NCT00144430
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.